Evaluation of the safety of nirmatrelvir-ritonavir in COVID patients at high risk
Among patients treated with nirmatrelvir-ritonavir, 64 patients reported the adverse effects. Out of these patients, 19 (29.7%) encountered at least one form of adverse effects, with gastrointestinal disorders (21.8%) being the prevailing side effects (Table 3).